Evidence map›Paper›PMID 23209159›Full record

ArticleCold Spring Harbor perspectives in medicine2013

The switch from fetal to adult hemoglobin.

Vijay G Sankaran, Stuart H Orkin

4 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Cold Spring Harbor perspectives in medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 154 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04586985 phase1completednot on this mapstarted 2020, after this paper: background citation

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics, With an Open-Label Initial Food Effect and CYP3A Drug-Drug Interaction Study, of FTX-6058 in Healthy Adult Subjects, and a Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study Evaluating, Safety, Tolerability and Pharmacokinetics in Subjects With Sickle Cell Disease (SCD)

TypeinterventionalSponsorFulcrum TherapeuticsRan2020 to 2022Enrolled109ConditionsHealthy Adult Subjects, Sickle Cell DiseaseArmsFTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
NCT05169580 phase1completednot on this mapstarted 2021, after this paper: background citation

A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)

TypeinterventionalSponsorFulcrum TherapeuticsRan2021 to 2026Enrolled45ConditionsSickle Cell Disease, Sickle Cell AnemiaArmsPociredir oral capsule(s)
NCT05883254 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Detection of RNA Binding Protein Pumilio1 (PUM1) Expression in Patients With Sickle Cell Anemia and β-thalassemia Intermedia

TypeobservationalSponsorAssiut UniversityRan2023 to 2027Enrolled80ConditionsSickle Cell Disease, Beta Thalassemia IntermediaArmsRNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
NCT06440603 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Erythroid Krüppel Like Factor (EKLF) Gene Expression in β-thalassemia Patients

TypeobservationalSponsorRofaida Hassan AhmedRan2024 to 2027Enrolled150Conditionsβ-thalassemiaArmsPCR
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 2 syntheses or guidelines pooled it, 323 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Hemoglobins F, AInternational journal of laboratory hematology · 2020
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Vijay G SankaranDivision of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA. sankaran@broadinstitute.org
Stuart H Orkin
Dana-Farber Cancer Institute · USHarvard University · US

Funding

PATHOPHYSIOLOGY OF HUMAN BLOOD CELLST32HL007574 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI Daniel Evan Bauer · 1985 to 2026
$18.4M
MOLECULAR ANALYSIS OF NORMAL AND TYHALASSEMIC DNAR01HL032259 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2022
$8.8M
Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL032259NHLBI NIH HHS T32 HL007574NHLBI NIH HHS T32 HL007574-30
6 · The paper itself

Abstract

The fetal-to-adult hemoglobin switch and silencing of fetal hemoglobin (HbF) have been areas of long-standing interest among hematologists, given the fact that clinical induction of HbF production holds tremendous promise to ameliorate the clinical symptoms of sickle cell disease (SCD) and β-thalassemia. In this article, we discuss historic attempts to induce HbF that have resulted in some therapeutic approaches to manage SCD and β-thalassemia. We then go on to discuss how more recent molecular studies that have identified regulators, including BCL11A, MYB, and KLF1, hold great promise to develop targeted and more effective approaches for HbF induction. We go on to discuss strategies by which such approaches may be developed. Older studies in this field can provide important lessons for future studies aimed at developing more effective strategies for HbF induction, and we therefore chronologically cover the work accomplished as this field has evolved over the course of the past four decades.

Indexed as

AdultAnemia, Sickle Cellbeta-ThalassemiaCarrier ProteinsDNA-Binding ProteinsFetal HemoglobinHemoglobin AHumansKruppel-Like Transcription FactorsMolecular Targeted TherapyNuclear ProteinsNucleocytoplasmic Transport ProteinsRepressor ProteinsRNA-Binding ProteinsTranscriptional ActivationTranscription FactorsBCL11A protein, humanCarrier ProteinsDNA-Binding Proteinserythroid Kruppel-like factorFetal HemoglobinHemoglobin AKruppel-Like Transcription FactorsMYBBP1A protein, humanNuclear ProteinsNucleocytoplasmic Transport ProteinsRepressor ProteinsRNA-Binding ProteinsTranscription Factors

Identifiers

PMID23209159
PMCPMC3530042
OpenAlexW2170845283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.